Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia

Journal of Children's Orthopaedics

Volumn 4, Issue 6, 2010, Pages 507-517

  Birke, Oliver ^a   Schindeler, Aaron ^a,b   Ramachandran, Manoj ^c   Cowell, Chris T ^a,b   Munns, Craig F ^a,b   Bellemore, Michael ^a   Little, David G ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonate; Bone morphogenetic protein; Congenital pseudarthrosis of the tibia; Neurofibromatosis type 1; NF1

Indexed keywords

EID: 78649320537     PISSN: 18632521     EISSN: 18632548     Source Type: Journal    
DOI: 10.1007/s11832-010-0293-3     Document Type: Article

References (35)

1. Hefti F, Bollini G, Dungl P, Fixsen J, Grill F, Ippolito E, Romanus B, Tudisco C, Wientroub S (2000) Congenital pseudarthrosis of the tibia: history, etiology, classification, and epidemiologic data. J Pediatr Orthop B 9: 11-15.
2. Traub JA, O'Connor W, Masso PD (1999) Congenital pseudarthrosis of the tibia: a retrospective review. J Pediatr Orthop 19: 735-738.
3. Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, D'Astous JL, Santora SD, Viskochil DH (2006) Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 79: 143-148.
4. Schindeler A, Little DG (2008) Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 42: 616-622.
5. Ofluoglu O, Davidson RS, Dormans JP (2008) Prophylactic bypass grafting and long-term bracing in the management of anterolateral bowing of the tibia and neurofibromatosis-1. J Bone Joint Surg Am 90: 2126-2134.
6. Hardinge K (1972) Congenital anterior bowing of the tibia. The significance of the different types in relation to pseudarthrosis. Ann R Coll Surg Engl 51: 17-30.
7. Grill F, Bollini G, Dungl P, Fixsen J, Hefti F, Ippolito E, Romanus B, Tudisco C, Wientroub S (2000) Treatment approaches for congenital pseudarthrosis of tibia: results of the EPOS multicenter study. European Paediatric Orthopaedic Society (EPOS). J Pediatr Orthop B 9: 75-89.
8. Joseph B, Somaraju VV, Shetty SK (2003) Management of congenital pseudarthrosis of the tibia in children under 3 years of age: effect of early surgery on union of the pseudarthrosis and growth of the limb. J Pediatr Orthop 23: 740-746.
9. Joseph B, Mathew G (2000) Management of congenital pseudarthrosis of the tibia by excision of the pseudarthrosis, onlay grafting, and intramedullary nailing. J Pediatr Orthop B 9: 16-23.
10. Plawecki S, Carpentier E, Lascombes P, Prevot J, Robb JE (1990) Treatment of congenital pseudarthrosis of the tibia by the Ilizarov method. J Pediatr Orthop 10: 786-790.
11. Ghanem I, Damsin JP, Carlioz H (1997) Ilizarov technique in the treatment of congenital pseudarthrosis of the tibia. J Pediatr Orthop 17: 685-690.
12. Boero S, Catagni M, Donzelli O, Facchini R, Frediani PV (1997) Congenital pseudarthrosis of the tibia associated with neurofibromatosis-1: treatment with Ilizarov's device. J Pediatr Orthop 17: 675-684.
13. Grill F (1996) Treatment of congenital pseudarthrosis of tibia with the circular frame technique. J Pediatr Orthop B 5: 6-16.
14. Paley D, Catagni M, Argnani F, Prevot J, Bell D, Armstrong P (1992) Treatment of congenital pseudoarthrosis of the tibia using the Ilizarov technique. Clin Orthop Relat Res 280: 81-93.
15. Johnston CE (2002) Congenital pseudarthrosis of the tibia: results of technical variations in the Charnley-Williams procedure. J Bone Joint Surg Am 84-A: 1799-1810.
16. Anderson DJ, Schoenecker PL, Sheridan JJ, Rich MM (1992) Use of an intramedullary rod for the treatment of congenital pseudarthrosis of the tibia. J Bone Joint Surg Am 74: 161-168.
17. Dobbs MB, Rich MM, Gordon JE, Szymanski DA, Schoenecker PL (2004) Use of an intramedullary rod for treatment of congenital pseudarthrosis of the tibia a long-term follow-up study. J Bone Joint Surg Am 86A: 1186-1197.
18. Kim HW, Weinstein SL (2002) Intramedullary fixation and bone grafting for congenital pseudarthrosis of the tibia. Clin Orthop Relat Res 405: 250-257.
19. Mathieu L, Vialle R, Thevenin-Lemoine C, Mary P, Damsin JP (2008) Association of Ilizarov's technique and intramedullary rodding in the treatment of congenital pseudarthrosis of the tibia. J Child Orthop 2: 449-455.
20. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Borner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, Van. d V, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G, Mathevon H, McCoy G, Marsh D, Miller R, Munting E, Oevre S, Nordsletten L, Patel A, Pohl A, Rennie W, Reynders P, Rommens PM, Rondia J, Rossouw WC, Daneel PJ, Ruff S, Ruter A, Santavirta S, Schildhauer TA, Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne RB, Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T (2002) Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A: 2123-2134.
21. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S (2001) Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83-A(Suppl 1): S151-S158.
22. Richards BS, Oetgen ME, Johnston CE (2010) The use of rhBMP-2 for the treatment of congenital pseudarthrosis of the tibia: a case series. J Bone Joint Surg Am 92: 177-185.
23. Lee FY, Sinicropi SM, Lee FS, Vitale MG, Roye DP Jr, Choi IH (2006) Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases. J Bone Joint Surg Am 88: 627-633.
24. Oetgen ME, Richards BS (2010) Complications associated with the use of bone morphogenic protein in pediatric patients. J Pediatr Orthop 30: 192-198.
25. Fabeck L, Ghafil D, Gerroudj M, Baillon R, Delince P (2006) Bone morphogenetic protein 7 in the treatment of congenital pseudarthrosis of the tibia. J Bone Joint Surg Br 88: 116-118.
26. Schindeler A, Ramachandran M, Godfrey C, Morse A, McDonald M, Mikulec K, Little DG (2008) Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice. J Orthop Res 26: 65-74.
27. Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N (2005) Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 20: 2044-2052.
28. Crawford AH (1978) Neurofibromatosis in the pediatric patient. Orthop Clin North Am 9: 11-23.
29. Crawford AH Jr, Bagamery N (1986) Osseous manifestations of neurofibromatosis in childhood. J Pediatr Orthop 6: 72-88.
30. Whelan DB, Bhandari M, Stephen D, Kreder H, McKee MD, Zdero R, Schemitsch EH (2010) Development of the radiographic union score for tibial fractures for the assessment of tibial fracture healing after intramedullary fixation. J Trauma 68: 629-632.
31. Amanat N, McDonald M, Godfrey C, Bilston L, Little D (2007) Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 22: 867-876.
32. Johannesen J, Briody J, McQuade M, Little DG, Cowell CT, Munns CF (2009) Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease. Bone 45: 898-902.
33. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayehh G, Guarneri V, Desrouleaux Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23: 826-836.
34. Munns CF, Rauch F, Travers R, Glorieux FH (2005) Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 20: 1235-1243.
35. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294-1301.